ClearPoint Neuro (NASDAQ:CLPT) Posts Earnings Results, Misses Expectations By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT) released its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Up 3.0 %

Shares of CLPT traded up $0.50 on Wednesday, reaching $17.22. The stock had a trading volume of 239,041 shares, compared to its average volume of 204,522. ClearPoint Neuro has a twelve month low of $5.11 and a twelve month high of $19.22. The firm has a market capitalization of $475.01 million, a PE ratio of -24.96 and a beta of 1.03. The firm has a 50-day moving average of $16.62 and a 200 day moving average of $13.78.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Lake Street Capital lifted their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley raised their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.